Heinrich S, Lang H
Klinik für Allgemein-, Viszeral- und Transplantationschirurgie, Universitätsmedizin Mainz, Langenbeckstr. 1, 55131, Mainz, Deutschland.
Chirurg. 2015 Feb;86(2):125-31. doi: 10.1007/s00104-014-2881-0.
Chronic liver parenchymal diseases as well as cholestasis are established risk factors for liver failure after partial hepatectomy. As hepatocellular (HCC) and cholangiocellular (CCC) carcinoma often require extended resection due to the often considerable size of tumors - in an often priorly damaged liver - surgery for these entities is usually demanding. Due to the lack of potent systemic treatment for primary liver tumors, surgery remains the only potentially curative treatment option for CCC and most HCC; therefore, perioperative risk factors for liver failure should be reduced as far as possible.
In this study measures for reducing the risk of liver failure after extended liver resections were analyzed.
This analysis was based on a selective literature search in the Pubmed databank.
Medical measures can be used to lower the degree of steatosis or the inflammatory reaction of ischemia/reperfusion injury. In particular, biliary decompression should be achieved in obstructive jaundice prior to liver surgery, e.g. for hilar cholangiocarcinoma, as cholestasis impairs liver regeneration. Moreover, the future liver remnant volume after extended liver resection can be increased by embolization (PVE) or ligation of major branches of the portal vein. Similar results as for PVE regarding liver hypertrophy have been reported from unilateral selective internal radiotherapy (SIRT) although this effect appears prolonged and less impressive than after PVE. In addition, two-stage concepts for liver surgery, which are also based on the regenerative potential of the liver, may lower the complication rate and increase patient safety by increasing liver volume. However, conventional two-stage procedures harbor the risk of disease progression during the time lapse to the second step which contraindicates complete resection in 20-30 % of patients. In contrast to this, a complete tumor resection is possible in nearly all patients treated by the associating liver partition and portal vein ligation for staged hepatectomy (ALPPS) procedure but long-term results regarding tumor recurrence rate are scarce due to the limited experience with this novel technique.
The perioperative risks of extended liver resection can be lowered by technical and medical measures.
慢性肝实质疾病以及胆汁淤积是肝部分切除术后肝衰竭的既定危险因素。由于肝细胞癌(HCC)和胆管细胞癌(CCC)的肿瘤通常体积较大,往往需要进行扩大切除——而肝脏通常已预先受损——因此这些实体肿瘤的手术通常要求较高。由于缺乏针对原发性肝肿瘤的有效全身治疗方法,手术仍然是CCC和大多数HCC唯一可能的治愈性治疗选择;因此,应尽可能降低肝衰竭的围手术期危险因素。
本研究分析了降低扩大肝切除术后肝衰竭风险的措施。
该分析基于对PubMed数据库的选择性文献检索。
可采用医学措施降低脂肪变性程度或缺血/再灌注损伤的炎症反应。特别是,对于梗阻性黄疸,如肝门部胆管癌,应在肝脏手术前实现胆道减压,因为胆汁淤积会损害肝脏再生。此外,扩大肝切除术后的未来肝残余体积可通过栓塞(PVE)或门静脉主要分支结扎来增加。单侧选择性内放射治疗(SIRT)在肝脏肥大方面的效果与PVE相似,尽管这种效果似乎持续时间更长,但不如PVE显著。此外,基于肝脏再生潜力的肝手术两阶段概念,可能通过增加肝脏体积来降低并发症发生率并提高患者安全性。然而,传统的两阶段手术存在在进入第二步的时间间隔内疾病进展的风险,这使得20%至30%的患者无法进行完全切除。与此相反,几乎所有接受联合肝脏分隔和门静脉结扎分期肝切除术(ALPPS)的患者都可以进行完整的肿瘤切除,但由于这项新技术的经验有限,关于肿瘤复发率的长期结果尚少。
技术和医学措施可降低扩大肝切除的围手术期风险。